Overview

A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of YM060 once daily for female patients with diarrhea-predominant irritable bowel syndrome (D-IBS) for a long-term period (up to 52 weeks).
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Ramosetron